Department of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany.
Department of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany ; Department of Nutritional Science, Friedrich-Schiller-University, Jena, Germany.
PLoS One. 2014 Jan 27;9(1):e80169. doi: 10.1371/journal.pone.0080169. eCollection 2014.
OBJECTIVE: Experimental evidence revealed that obesity-associated non-alcoholic fatty liver disease (NAFLD) is linked to changes in intestinal permeability and translocation of bacterial products to the liver. Hitherto, no reliable therapy is available except for weight reduction. Within this study, we examined the possible effect of the probiotic bacterial strain Lactobacillus rhamnosus GG (LGG) as protective agent against experimental NAFLD in a mouse model. METHODS: Experimental NAFLD was induced by a high-fructose diet over eight weeks in C57BL/J6 mice. Fructose was administered via the drinking water containing 30% fructose with or without LGG at a concentration resulting in approximately 5×10(7) colony forming units/g body weight. Mice were examined for changes in small intestinal microbiota, gut barrier function, lipopolysaccharide (LPS) concentrations in the portal vein, liver inflammation and fat accumulation in the liver. RESULTS: LGG increased beneficial bacteria in the distal small intestine. Moreover, LGG reduced duodenal IκB protein levels and restored the duodenal tight junction protein concentration. Portal LPS (P≤0.05) was reduced and tended to attenuate TNF-α, IL-8R and IL-1β mRNA expression in the liver feeding a high-fructose diet supplemented with LGG. Furthermore liver fat accumulation and portal alanine-aminotransferase concentrations (P≤0.05) were attenuated in mice fed the high-fructose diet and LGG. CONCLUSIONS: We show for the first time that LGG protects mice from NAFLD induced by a high-fructose diet. The underlying mechanisms of protection likely involve an increase of beneficial bacteria, restoration of gut barrier function and subsequent attenuation of liver inflammation and steatosis.
目的:实验证据表明,与肥胖相关的非酒精性脂肪性肝病(NAFLD)与肠道通透性的变化和细菌产物向肝脏的易位有关。迄今为止,除了减肥之外,尚无可靠的治疗方法。在这项研究中,我们研究了益生菌菌株鼠李糖乳杆菌 GG(LGG)作为实验性非酒精性脂肪性肝病保护剂在小鼠模型中的可能作用。
方法:通过八周的高果糖饮食在 C57BL/J6 小鼠中诱导实验性非酒精性脂肪性肝病。果糖通过饮用水中的 30%果糖给药,其中含有或不含有浓度约为 5×10(7)个菌落形成单位/克体重的 LGG。检查小鼠小肠微生物群、肠道屏障功能、门静脉内脂多糖(LPS)浓度、肝脏炎症和肝脏脂肪堆积的变化。
结果:LGG 增加了远端小肠中的有益细菌。此外,LGG 降低了空肠 IκB 蛋白水平并恢复了空肠紧密连接蛋白浓度。补充 LGG 的高果糖饮食可降低门静脉 LPS(P≤0.05),并倾向于减轻肝脏中 TNF-α、IL-8R 和 IL-1β mRNA 的表达。此外,高果糖饮食和 LGG 喂养的小鼠肝脏脂肪堆积和门静脉丙氨酸氨基转移酶浓度(P≤0.05)减轻。
结论:我们首次表明,LGG 可保护小鼠免受高果糖饮食引起的非酒精性脂肪性肝病的侵害。保护的潜在机制可能涉及有益细菌的增加、肠道屏障功能的恢复以及随后的肝脏炎症和脂肪变性的减轻。
Am J Physiol Gastrointest Liver Physiol. 2012-4-26
Biochem Biophys Res Commun. 2016-4-29
J Nutr Biochem. 2012-6-27
World J Hepatol. 2025-8-27
Probiotics Antimicrob Proteins. 2025-7-11
World J Hepatol. 2025-6-27
Microorganisms. 2024-12-3
Metabolites. 2024-12-13
Probiotics Antimicrob Proteins. 2025-4
Endocr J. 2013-4-19
Korean J Gastroenterol. 2012-8
J Nutr Biochem. 2012-6-27
Ann Hepatol. 2012
Am J Physiol Gastrointest Liver Physiol. 2012-4-26
Nat Rev Gastroenterol Hepatol. 2012-2-21